Business Standard

Flu season starts, but demand for cough-cold meds remains weak

Impact in US among the worst in the past 10 years

Pharmacy
Premium

Photo: Shutterstock

Sohini Das Mumbai
Demand in India for cough and cold medicines remained weak even as the US witnessed one of the worst beginnings to the season the past decade.
 
Analysts at Nuvama Research said key findings show five times more illness versus the average of the last five years, eight times more hospital visits, and 3.5 times more deaths this season in the US.
 
Indian companies stand to gain as a result of a strong flu season as they enjoy a one-third share of the total prescription market in Oseltamivir (flu medicine) suspension market.
 
Oseltamivir is the first-line treatment for Influenza A and

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in